GRCE

MKT CAP:$35M

Grace Therapeutics, Inc.

Market Cap

$35M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$2.27-$1.39 (-37.84%)

Apr 24, 2026

Company Details

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid ...

CEO

Prashant Kohli

IPO Date

Feb 7, 2012

Website

www.acastipharma.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$8M

EPS (Diluted)

-$0.58

Free Cash Flow

-$12M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q2 2026

Nov 13, 2025

$0EPS -$0.06

Q1 2026

Aug 12, 2025

$0EPS -$0.21

FY 2025

Jun 23, 2025

$0EPS -$0.79

Q4 2025

Jun 23, 2025

$0EPS $0.05

Q3 2025

Feb 13, 2025

$0EPS -$0.36

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 22	$0	$0	-$4M
Q4 22	$0	$0	-$4M
Q1 23	$0	$0	-$5M
Q2 23	$0	$0	-$5M
Q3 23	$0	$0	-$4M
Q4 23	$0	$0	-$38M
Q1 24	$0	$0	-$4M
Q2 24	$0	-$2.0K	-$2M
Q3 24	$0	$0	-$3M
Q4 24	$0	-$1.0K	-$3M
Q1 25	$0	$0	-$5M
Q2 25	$0	$0	-$5M
Q3 25	$0	$0	-$4M
Q4 25	$0	-$2.0K	-$3M
Q1 26	$0	$0	-$3M
Q2 26	$0	$0	-$3M

Valuation

Quarter	P/S	P/E
Q3 22	311.2x	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—
Q1 26	—	—
Q2 26	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 22	-$5M	-$5M
Q4 22	-$3M	-$3M
Q1 23	-$5M	-$5M
Q2 23	-$3M	-$3M
Q3 23	-$4M	-$4M
Q4 23	-$3M	-$3M
Q1 24	-$6M	-$6M
Q2 24	-$2M	-$2M
Q3 24	-$2M	-$2M
Q4 24	-$2M	-$2M
Q1 25	-$4M	-$4M
Q2 25	-$4M	-$4M
Q3 25	-$4M	-$4M
Q4 25	-$3M	-$3M
Q1 26	-$2M	-$2M
Q2 26	-$3M	-$3M

Capital Expenditures

Quarter	CapEx
Q3 22	$0
Q4 22	$0
Q1 23	$7.0K
Q2 23	$2.0K
Q3 23	$0
Q4 23	$8.0K
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$22.0K
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$0
Q1 26	$0
Q2 26	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 22	-100.0%	+118.8%
Q4 22	-100.0%	+82.3%
Q1 23	—	+50.4%
Q2 23	—	+40.1%
Q3 23	—	-5.1%
Q4 23	—	+764.7%
Q1 24	—	-5.8%
Q2 24	—	-58.2%
Q3 24	—	-28.3%
Q4 24	—	-91.4%
Q1 25	—	+11.4%
Q2 25	—	+131.4%
Q3 25	—	+21.7%
Q4 25	—	-2.5%
Q1 26	—	-37.7%
Q2 26	—	-47.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 22	$454.0K	—
Q4 22	$616.0K	—
Q1 23	$464.0K	—
Q2 23	$582.0K	—
Q3 23	$443.0K	—
Q4 23	$322.0K	—
Q1 24	$78.0K	—
Q2 24	$280.0K	—
Q3 24	$326.0K	—
Q4 24	$229.0K	—
Q1 25	$238.0K	—
Q2 25	$202.0K	—
Q3 25	$160.0K	—
Q4 25	$130.0K	—
Q1 26	$302.0K	—
Q2 26	$0	—

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q3 22	$2M	$2M	$78.0K	—
Q4 22	$2M	$2M	$255.0K	—
Q1 23	$3M	$2M	$10.0K	—
Q2 23	$3M	—	—	$2M
Q3 23	$2M	$2M	$72.0K	—
Q4 23	$2M	$2M	$51.0K	—
Q1 24	$1M	$2M	—	—
Q2 24	$456.0K	—	—	$2M
Q3 24	$1M	$2M	$30.0K	—
Q4 24	$2M	—	—	$2M
Q1 25	$3M	$2M	—	—
Q2 25	$3M	$2M	—	—
Q3 25	$2M	$2M	—	—
Q4 25	$2M	—	—	$2M
Q1 26	$955.0K	$2M	—	—
Q2 26	$568.0K	$2M	—	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$30M	$13M	$44M
Q1 23	$38M	$16.0K	$38M
Q2 23	$35M	$14.0K	$35M
Q3 23	$26M	$5M	$31M
Q4 23	$28M	$15.0K	$28M
Q1 24	$22M	$15.0K	$22M
Q2 24	$27M	$15.0K	$27M
Q3 24	$19M	$7M	$25M
Q4 24	$23M	$0	$23M
Q1 25	$19M	$15.0K	$19M
Q2 25	$15M	$15.0K	$15M
Q3 25	$11M	$0	$11M
Q4 25	$22M	$0	$22M
Q1 26	$20M	$0	$20M
Q2 26	$17M	$0	$17M
Q3 26	$19M	$0	$19M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 22	7M	+35.1%	+253.3%
Q4 22	7M	-8.4%	+98.6%
Q1 23	7M	+9.2%	+70.2%
Q2 23	7M	+0.5%	+35.9%
Q3 23	7M	+0.1%	+0.7%
Q4 23	7M	+0.0%	+9.9%
Q1 24	7M	+0.0%	+0.6%
Q2 24	8M	+1.6%	+1.7%
Q3 24	7M	-0.8%	+0.8%
Q4 24	9M	+22.5%	+23.5%
Q1 25	11M	+19.0%	+47.0%
Q2 25	12M	+5.3%	+52.3%
Q3 25	12M	0.0%	+53.5%
Q4 25	14M	+19.2%	+49.4%
Q1 26	16M	+16.1%	+45.7%
Q2 26	16M	0.0%	+38.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 22	$0	3
Q4 22	$0	3
Q1 23	$0	3
Q2 23	$0	3
Q3 23	$0	3
Q4 23	$0	3
Q1 24	$0	3
Q2 24	$0	3
Q3 24	$0	3
Q4 24	$0	4
Q1 25	$0	4
Q2 25	$0	4
Q3 25	$0	4
Q4 25	$0	6
Q1 26	$0	6
Q2 26	$0	6

Revenue / Employee